Argus analyst David Toung believes Bio-Techne remains on-track for continued solid revenue growth driven by strong domestic and international demand for its products. He lowered his estimates to reflect earnings dilution from its recent acquisition, but noted the company is targeting $1B in revenues by 2022. Toung reiterated his Buy rating and $230 price target on Bio-Techne shares.
https://thefly.com/landingPageNews.php?id=2873575
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.